

12 November 2021

ASX Code: MXC

LSE Code: MXC

Jobkeeper Section 323DB Notification

A
S
X

R
E
L
E
A
S
E

In accordance with section 323DB of the Corporations Act 2001 (Cth), **MGC Pharmaceuticals Ltd** ('**MGC Pharma**' or '**the Company**') provides the attached Notice in relation to Jobkeeper payments received by MGC Pharma or its subsidiaries in the financial years ended 30 June 2020 and 2021.

--Ends--

Authorised for release by the Managing Director, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6382 3390
info@mgcpharma.com.au

UK Broker – Turner Pope

Andy Thacker
+44 203 657 0050
info@turnerpope.com

MGC Pharmaceuticals Ltd

David Lim
Company Secretary
+61 8 6382 3390
info@mgcpharma.com.au

UK PR Advisors – Tavistock

Charles Vivian / Tim Pearson
+44 207 920 3150
mgcpharma@tavistock.co.uk

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels



Jobkeeper Payments Notification

*A notice for release to the market under subsection 323DB(1) of the Corporations Act 2001-
jobkeeper payments disclosure by listed entity.*

Date of this notice

12/11/2021

Listed entity details

Australian Business Number (ABN)

30116800269

ASX/NSX/SSX issuer code

MXC

Name of the listed entity

MGC Pharmaceuticals Ltd

Jobkeeper payments

This notice relates to the financial years ended 30/06/2020 (FY 1) and 30/06/2021 (FY 2).

The number of individuals for whom the listed entity or a subsidiary of the listed entity received a jobkeeper payment for a jobkeeper fortnight that ended in the financial year (within the meaning of the Coronavirus Economic Response Package (Payments and Benefits) Rules 2020).

FY 1: 1

FY 2: 1

The sum of all jobkeeper payments the listed entity, and each subsidiary of the listed entity, received in a jobkeeper fortnight that ended in the financial year.

FY 1: \$9,000

FY 2: \$7,500

Has the listed entity or a subsidiary of the listed entity, made one or more voluntary payments (whether or not in the financial year) to the Commonwealth by way of a repayment of jobkeeper payments received by the listed entity or a subsidiary of the listed in the financial year?

NO

If the listed entity or a subsidiary of the listed entity has made such a voluntary payment or payments -the sum of those payments:

FY 1:\$0

FY 2:\$0